Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of carmustine wafers with radiotherapy, bevacizumab, and temozolomide for totally resected newly diagnosed glioblastoma
jRCTs021180007Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine, bevacizumab and temozolomide in glioblastoma (GBM), sponsored by Eisai Co., Ltd. Primary endpoint: 2-year overall survival rate. Started Feb 2016; status: completed.
02
Drugs
carmustinebevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCTs021180007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180007.